Search for content, post, videos

Novo Nordisk’s Ozempic 2.0 mg approved in the US

Martin Holst Lange
Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved a 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analogue for the treatment of adults with type 2 diabetes. Ozempic is now approved in the US at 0.5 m
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.